Document Type
Article
Publication Date
1-1-2025
Abstract
Tryptophan (Trp)-based radiotracers have excellent potential for imaging many different types of brain pathology because of their involvement with both the serotonergic and kynurenine (KYN) pathways. However, radiotracers specific to the kynurenine metabolism pathway are limited. In addition, historically Trp-based radiopharmaceuticals were synthesized with the short-lived isotope carbon-11. A newer generation of Trp-based imaging agents using the longer half-lived and commercially available isotopes, such as fluorine-18 and iodine-124, are being developed. The newly developed amino acid-based tracers have been demonstrated to have favorable radiochemical and imaging characteristics in pre-clinical studies. However, many barriers still exist in the clinical translation of KYN pathway-specific radiotracers.
Recommended Citation
Stauff, Erik; Xu, Wenqi; Kecskemethy, Heidi H.; Langhans, Sigrid A.; Kandula, Vinay V. R.; Averill, Lauren W.; and Yue, Xuyi, "Tryptophan Kynurenine Pathway-Based Imaging Agents for Brain Disorders and Oncology-From Bench to Bedside" (2025). Jefferson Hospital Staff Papers and Presentations. Paper 47.
https://jdc.jefferson.edu/tjuhpapers/47
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Language
English
Included in
Amino Acids, Peptides, and Proteins Commons, Chemical Actions and Uses Commons, Neurology Commons, Radiology Commons
Comments
This article is the author's final published version in Biomolecules, Volume 15, Issue 1, January 2025, Article number 47.
The published version is available https://doi.org/10.3390/biom15010047.
Copyright © 2025 by the authors